Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages.
Two studies were performed in children with cystic fibrosis (CF) to compare the efficacy and tolerability of pancreatic enzymes prepared as enteric-coated microspheres with that of a conventional enzyme preparation. The parameters evaluated included the following: fecal fat excretion, coefficient of fat absorption, daily caloric intake, percent of diet as fats, proteins and carbohydrates, increase in height and weight, frequency and consistency of stools, palatability of the preparation, and patient compliance. The first study was an open randomized crossover trial of an enteric-coated microsphere preparation (Pancrease) versus conventional pancreatin given alone or with cimetidine. With Pancrease compared to conventional pancreatin, a significant improvement was observed in all the digestive parameters in addition to better patient compliance. In the second study, the response of a group of CF patients given Pancrease for at least 3 months (3-67 months) was retrospectively compared with the response to conventional pancreatin, which had been given to the same patients from 10 months to 8 years earlier. In comparison to conventional pancreatin, Pancrease provided better digestive efficacy and greater increases in the growth rate of teenage patients. With Pancrease, the number of daily dosage units is decreased even when fat intake is increased. No adverse reactions were seen with either of the enzyme preparations used in these studies.
D000293:Adolescent; D000367:Age Factors; D002446:Celiac Disease / Q000188:drug therapy / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D007408:Intestinal Absorption; D008049:Lipase / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D008863:Microspheres; D010184:Pancreatic Extracts / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010194:Pancreatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D020799:Pancrelipase; D011897:Random Allocation; D012189:Retrospective Studies; D012737:Sex Factors
D010184:Pancreatic Extracts; D020799:Pancrelipase; D002927:Cimetidine; D010194:Pancreatin; D008049:Lipase